Immunotherapy: remember the host

doi:10.21037/tlcr-23-743

Editorial

. 2023 Dec 26;12(12):2366-2369.

doi: 10.21037/tlcr-23-743. Epub 2023 Dec 15.

Immunotherapy: remember the host

Paul R Walker¹

Affiliations

PMID: 38205215
PMCID: PMC10775002
DOI: 10.21037/tlcr-23-743

Editorial

Immunotherapy: remember the host

Paul R Walker. Transl Lung Cancer Res. 2023.

. 2023 Dec 26;12(12):2366-2369.

doi: 10.21037/tlcr-23-743. Epub 2023 Dec 15.

Author

Paul R Walker¹

Affiliation

¹ Division of Hematology/Oncology, Department of Medicine, Brody School of Medicine at East Carolina University, Greenville, NC, USA.

PMID: 38205215
PMCID: PMC10775002
DOI: 10.21037/tlcr-23-743

No abstract available

Keywords: Immunotherapy; biomarkers; host.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The author has completed the ICMJE uniform disclosure form (available at https://tlcr.amegroups.com/article/view/10.21037/tlcr-23-743/coif). P.R.W. is a current employee of Circulogene. The author has no other conflicts of interest to declare.

Comment on

Prognostic value of baseline and early treatment response of neutrophil-lymphocyte ratio, C-reactive protein, and lactate dehydrogenase in non-small cell lung cancer patients undergoing immunotherapy.
Sung M, Jang WS, Kim HR, Park JA, Lim SM, Kim HR, Cho BC, Park YR, Hong MH. Sung M, et al. Transl Lung Cancer Res. 2023 Jul 31;12(7):1506-1516. doi: 10.21037/tlcr-23-7. Epub 2023 Jul 14. Transl Lung Cancer Res. 2023. PMID: 37577328 Free PMC article.

Cited by

An Updated Review of Management of Resectable Stage III NSCLC in the Era of Neoadjuvant Immunotherapy.
Verma S, Breadner D, Mittal A, Palma DA, Nayak R, Raphael J, Vincent M. Verma S, et al. Cancers (Basel). 2024 Mar 27;16(7):1302. doi: 10.3390/cancers16071302. Cancers (Basel). 2024. PMID: 38610980 Free PMC article. Review.

References

1. Sung M, Jang WS, Kim HR, et al. Prognostic value of baseline and early treatment response of neutrophil-lymphocyte ratio, C-reactive protein, and lactate dehydrogenase in non-small cell lung cancer patients undergoing immunotherapy. Transl Lung Cancer Res 2023;12:1506-16. 10.21037/tlcr-23-7 - DOI - PMC - PubMed
1. de Castro G, Jr, Kudaba I, Wu YL, et al. Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non-Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 Study. J Clin Oncol 2023;41:1986-91. 10.1200/JCO.21.02885 - DOI - PMC - PubMed
1. Rodríguez-Abreu D, Powell SF, Hochmair MJ, et al. Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189. Ann Oncol 2021;32:881-95. 10.1016/j.annonc.2021.04.008 - DOI - PubMed
1. Bhutiani N, Wargo JA. Gut microbes as biomarkers of ICI response - sharpening the focus. Nat Rev Clin Oncol 2022;19:495-6. 10.1038/s41571-022-00634-0 - DOI - PubMed
1. Liu N, Mao J, Tao P, et al. The relationship between NLR/PLR/LMR levels and survival prognosis in patients with non-small cell lung carcinoma treated with immune checkpoint inhibitors. Medicine (Baltimore) 2022;101:e28617. 10.1097/MD.0000000000028617 - DOI - PMC - PubMed

Publication types

Actions
Actions

LinkOut - more resources

Full Text Sources

[1] Sung M, Jang WS, Kim HR, et al. Prognostic value of baseline and early treatment response of neutrophil-lymphocyte ratio, C-reactive protein, and lactate dehydrogenase in non-small cell lung cancer patients undergoing immunotherapy. Transl Lung Cancer Res 2023;12:1506-16. 10.21037/tlcr-23-7 - DOI - PMC - PubMed

[2] Sung M, Jang WS, Kim HR, et al. Prognostic value of baseline and early treatment response of neutrophil-lymphocyte ratio, C-reactive protein, and lactate dehydrogenase in non-small cell lung cancer patients undergoing immunotherapy. Transl Lung Cancer Res 2023;12:1506-16. 10.21037/tlcr-23-7 - DOI - PMC - PubMed

[3] de Castro G, Jr, Kudaba I, Wu YL, et al. Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non-Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 Study. J Clin Oncol 2023;41:1986-91. 10.1200/JCO.21.02885 - DOI - PMC - PubMed

[4] de Castro G, Jr, Kudaba I, Wu YL, et al. Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non-Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 Study. J Clin Oncol 2023;41:1986-91. 10.1200/JCO.21.02885 - DOI - PMC - PubMed

[5] Rodríguez-Abreu D, Powell SF, Hochmair MJ, et al. Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189. Ann Oncol 2021;32:881-95. 10.1016/j.annonc.2021.04.008 - DOI - PubMed

[6] Rodríguez-Abreu D, Powell SF, Hochmair MJ, et al. Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189. Ann Oncol 2021;32:881-95. 10.1016/j.annonc.2021.04.008 - DOI - PubMed

[7] Bhutiani N, Wargo JA. Gut microbes as biomarkers of ICI response - sharpening the focus. Nat Rev Clin Oncol 2022;19:495-6. 10.1038/s41571-022-00634-0 - DOI - PubMed

[8] Bhutiani N, Wargo JA. Gut microbes as biomarkers of ICI response - sharpening the focus. Nat Rev Clin Oncol 2022;19:495-6. 10.1038/s41571-022-00634-0 - DOI - PubMed

[9] Liu N, Mao J, Tao P, et al. The relationship between NLR/PLR/LMR levels and survival prognosis in patients with non-small cell lung carcinoma treated with immune checkpoint inhibitors. Medicine (Baltimore) 2022;101:e28617. 10.1097/MD.0000000000028617 - DOI - PMC - PubMed

[10] Liu N, Mao J, Tao P, et al. The relationship between NLR/PLR/LMR levels and survival prognosis in patients with non-small cell lung carcinoma treated with immune checkpoint inhibitors. Medicine (Baltimore) 2022;101:e28617. 10.1097/MD.0000000000028617 - DOI - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Immunotherapy: remember the host

Affiliation

Immunotherapy: remember the host

Author

Affiliation

Conflict of interest statement

Comment on

Similar articles

Cited by

References

Publication types

LinkOut - more resources

Full Text Sources